image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - GB
$ 9.24
0.544 %
$ 41.8 B
Market Cap
28.88
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one HLN stock under the worst case scenario is HIDDEN Compared to the current market price of 9.24 USD, Haleon plc is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one HLN stock under the base case scenario is HIDDEN Compared to the current market price of 9.24 USD, Haleon plc is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one HLN stock under the best case scenario is HIDDEN Compared to the current market price of 9.24 USD, Haleon plc is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
11.3 B REVENUE
4.09%
2 B OPERATING INCOME
9.37%
1.11 B NET INCOME
-0.71%
2.1 B OPERATING CASH FLOW
1.79%
-134 M INVESTING CASH FLOW
98.47%
-1.57 B FINANCING CASH FLOW
-22.69%
2.78 B REVENUE
-4.93%
496 M OPERATING INCOME
-25.08%
303 M NET INCOME
-28.37%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Haleon plc
image
Current Assets 4.82 B
Cash & Short-Term Investments 1.04 B
Receivables 1.35 B
Other Current Assets 2.42 B
Non-Current Assets 29.2 B
Long-Term Investments 65 M
PP&E 1.9 B
Other Non-Current Assets 27.3 B
Current Liabilities 4.64 B
Accounts Payable 1.86 B
Short-Term Debt 656 M
Other Current Liabilities 2.13 B
Non-Current Liabilities 12.7 B
Long-Term Debt 8.8 B
Other Non-Current Liabilities 3.89 B
EFFICIENCY
Earnings Waterfall Haleon plc
image
Revenue 11.3 B
Cost Of Revenue 4.34 B
Gross Profit 6.96 B
Operating Expenses 4.96 B
Operating Income 2 B
Other Expenses 885 M
Net Income 1.11 B
RATIOS
59.70% GROSS MARGIN
59.70%
17.66% OPERATING MARGIN
17.66%
9.28% NET MARGIN
9.28%
6.32% ROE
6.32%
3.08% ROA
3.08%
5.25% ROIC
5.25%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Haleon plc
image
Net Income 1.11 B
Depreciation & Amortization 309 M
Capital Expenditures -336 M
Stock-Based Compensation 76 M
Change in Working Capital -107 M
Others 585 M
Free Cash Flow 1.76 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Haleon plc
image
Wall Street analysts predict an average 1-year price target for HLN of $9.15 , with forecasts ranging from a low of $9.15 to a high of $9.15 .
HLN Lowest Price Target Wall Street Target
9.15 USD -0.97%
HLN Average Price Target Wall Street Target
9.15 USD -0.97%
HLN Highest Price Target Wall Street Target
9.15 USD -0.97%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.0514 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Haleon plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Haleon: Guidance Implies Uncertainty Around Flu Season Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3. seekingalpha.com - 1 month ago
Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024. prnewswire.com - 1 month ago
Dividend Income: Lanny's October 2024 Summary Big Oil with BHP Billiton came big with a massive dividend. Canadian Imperial, one of the big 6 Canadian banks, sent a massive $210 dividend my way. There are a few less names now in 2024 than 2023, such as MDU Resources and Haleon. seekingalpha.com - 2 months ago
Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy globenewswire.com - 2 months ago
Haleon plc (HLN) Q3 2024 Sales Call Transcript Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO. seekingalpha.com - 2 months ago
Panadol maker Haleon takes hit from currency headwinds Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%. proactiveinvestors.co.uk - 2 months ago
Haleon reports marginal decline in third-quarter revenue Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments. reuters.com - 2 months ago
Haleon gets target hike as UBS raises 'forever' sales target Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth. proactiveinvestors.co.uk - 3 months ago
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores. proactiveinvestors.co.uk - 3 months ago
HLN or PODD: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Insulet (PODD). But which of these two stocks is more attractive to value investors? zacks.com - 3 months ago
Haleon's buy rating restated after Pfizer cuts down stake UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion. proactiveinvestors.co.uk - 3 months ago
Haleon buys back some shares as Pfizer sells down stake Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker.  The FTSE 100 consumer health group said made the purchase at a price of 308p per share. proactiveinvestors.co.uk - 3 months ago
8. Profile Summary

Haleon plc HLN

image
COUNTRY GB
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 41.8 B
Dividend Yield 0.00%
Description Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Contact Building 5, Weybridge, KT13 0NY https://www.haleon.com
IPO Date July 25, 2022
Employees 25408
Officers Ms. Line De Decker Chief Human Resources Officer Mr. Filippo Lanzi President of EMEA & LatAm Ms. Lisa Paley President of North America Ms. Dawn Amanda Allen Chief Financial Officer & Director Ms. Claire Dickson Chief Digital & Technology Officer Ms. Tamara Rogers Chief Marketing Officer Ms. Sonya Ghobrial Head of Investor Relations Mr. Brian James McNamara Chief Executive Officer & Executive Director Mr. Keith Choy President of Asia Pacific Mr. Adrian Charles Morris General Counsel